Tag Archives: opko

OPKO Health’s BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing

BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women’s and Men’s National Soccer Teams, Winter X Games and NBA G League ELMWOOD PARK, N.J., January 26, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well […]

OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access

Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ELMWOOD PARK, N.J., January 13, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic […]

OPKO Health’s BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47% ELMWOOD PARK, N.J., (January 4, 2021) – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City’s boroughs, with a positivity rate of […]

Buffalo Bills and OPKO Health’s BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program

The Bills leverage testing capabilities from NFL testing provider, BioReference, to initiate fan testing program ORCHARD PARK, N.Y., December 31, 2020 – Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at […]

OPKO Health’s BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]

OPKO Health’s BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]

OPKO Health’s BioReference Laboratories Announces New York City Schools COVID-19 Testing Program

The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]

OPKO Health’s BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay

ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight AdvancedNGS testing provides targeted gene content that is aligned with the latest […]

OPKO Health’s BioReference Laboratories Expands Contract With Blue Cross and Blue Shield of Texas to Include All Plans and Products

ELMWOOD PARK, N.J., August 18, 2020 – BioReference Laboratories Inc., an OPKO Health Company, is pleased to announce it is now in-network with all Blue Cross and Blue Shield of Texas (BCBSTX) products, including its Health Maintenance Organization (HMO) and Medicaid lines of business. The contract includes BioReference’s subsidiary GeneDx, Inc., a full service genetics […]

OPKO Health’s GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services

GAITHERSBURG, Md., August 12, 2020 – GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), the global leader in neonatal and pediatric genetic testing, announced the entrance into an agreement with Pediatrix Medical Group (“Pediatrix”), the nation’s leading provider of maternal-fetal, and pediatric medical and surgical subspecialty physician services, to offer state-of-the-art, […]